Soligenix Inc., of Princeton, N.J., enrolled and treated all patients in a Phase I trial of SGX203 for pediatric Crohn's disease. The goal of the 24-subject study was to characterize the drug's pharmacokinetic and pharmacodynamic profile of the formulation.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-855-260-5607
Outside the U.S.: 1-646-822-4549
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter